Jazz Pharmaceuticals (JAZZ) Revenue (2010 - 2026)

Jazz Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Revenue rose 19.06% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 9.2% YoY), while the FY2025 annual figure was $4.3 billion, up 4.88% from the prior year.
• Revenue was $1.1 billion for Q1 2026 at Jazz Pharmaceuticals, down from $1.2 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $1.2 billion in Q4 2025 to a low of $813.7 million in Q1 2022.
• Historically, Revenue has averaged $994.1 million across 5 years, with a median of $972.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue surged 33.93% in 2022, then fell 0.46% in 2025.
• A 5-year view of Revenue shows it stood at $972.1 million in 2022, then climbed by 4.1% to $1.0 billion in 2023, then grew by 7.53% to $1.1 billion in 2024, then advanced by 10.09% to $1.2 billion in 2025, then fell by 10.77% to $1.1 billion in 2026.
• The last three Revenue figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.